The Strides-backed protein and peptide-based therapeutics developer has disclosed a $70m series B and $125m C round, valuing it at $350m post-money.
Stelis Biopharma, an India-based drug and vaccine developer spun off by pharmaceutical firm Strides Pharma Science, announced in a stock exchange filing today it has secured $195m across series B and C rounds.
Private equity firm TPG Growth joined returning investors Route One, Think Investments and the Mankekar Family to co-lead the $125m series C round, which included a primary transaction of $85m and a $40m secondary share sale by existing shareholder GMS. It valued Stelis at $350m post-money.
…
